Table 1.

Baseline participant characteristics.

Parameter	IM CAB+RPV LA Q2M arm n = 90	Oral DTG/RPV QD arm n = 7	Total N = 97
Age, median (range) years	41 (25–63)	53 (30–62)	41 (25–63)
Age ≥50 years, n (%)	16 (18)	4 (57)	20 (21)
Female (sex at birth), n (%)	2 (2)	0	2 (2)
Female (self-reported sex), n (%)	3 (3)	0	3 (3)
Race, n (%)
White	63 (70)	4 (57)	67 (69)
Black or African–American	21 (23)	3 (43)	24 (25)
Other	6 (7)	0	6 (6)
BMI, median (range) kg/m2	27 (19–48)	27 (24–31)	27 (19–48)
CD4+ cell count, median (range) cells/μl	851 (376–1593)	779 (595–1050)	842 (376–1593)

Table 1 was presented previously at IDWeek; October 21–25, 2020; Virtual; Oral.

CAB, cabotegravir; DTG, dolutegravir; IM, intramuscular; LA, long-acting; QD, once daily; Q2M, every 2 months; RPV, rilpivirine.